Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Bachman

Eppendorf announced that Thomas Bachman was appointed CEO on August 1, 2015. Bachman is taking over for Detmar Ammerman, who took on the role of CEO in addition to his responsibilities as CFO upon the departure of the previous CEO. Bachman has been a member of Eppendorf's supervisory board since 2013. Before joining Eppendorf, he held a position as president of Burker BioSpin. He has been active in the life science sector since 2005, when he managed the Tecan group, headquartered in Switzerland.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.